# Neoadjuvant Endostatin and Chemotherapy for Breast Cancer

> **NCT00604435** · PHASE2 · COMPLETED · sponsor: **Xijing Hospital** · enrollment: 69 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** docetaxel and epirubicin
- **DRUG:** docetaxel and epirubicin plus endostatin

## Key facts

- **NCT ID:** NCT00604435
- **Lead sponsor:** Xijing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-01
- **Final completion:** 2010-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2010-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00604435

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00604435, "Neoadjuvant Endostatin and Chemotherapy for Breast Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00604435. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*